[go: up one dir, main page]

WO2006012419A3 - Inhibition of nf-kb - Google Patents

Inhibition of nf-kb Download PDF

Info

Publication number
WO2006012419A3
WO2006012419A3 PCT/US2005/025884 US2005025884W WO2006012419A3 WO 2006012419 A3 WO2006012419 A3 WO 2006012419A3 US 2005025884 W US2005025884 W US 2005025884W WO 2006012419 A3 WO2006012419 A3 WO 2006012419A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
aminoacridines
reactivation
inhibitors
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/025884
Other languages
French (fr)
Other versions
WO2006012419A2 (en
Inventor
Andrei V Gudkov
Katerina V Gurova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Priority to JP2007522754A priority Critical patent/JP2008507545A/en
Priority to AU2005267117A priority patent/AU2005267117C1/en
Priority to EP05791579A priority patent/EP1771203A4/en
Publication of WO2006012419A2 publication Critical patent/WO2006012419A2/en
Priority to US11/624,828 priority patent/US20070270455A1/en
Anticipated expiration legal-status Critical
Publication of WO2006012419A3 publication Critical patent/WO2006012419A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)

Abstract

Aminoacridines are inhibitors of NF-κB. Inhibiting NF-κB leads to reactivation of p53 in cancer cells with functionally blocked p53.
PCT/US2005/025884 2004-07-20 2005-07-20 Inhibition of nf-kb Ceased WO2006012419A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007522754A JP2008507545A (en) 2004-07-20 2005-07-20 Inhibition of NF-κB
AU2005267117A AU2005267117C1 (en) 2004-07-20 2005-07-20 Inhibition of NF-KB
EP05791579A EP1771203A4 (en) 2004-07-20 2005-07-20 Inhibition of nf-kb
US11/624,828 US20070270455A1 (en) 2005-07-20 2007-01-19 INHIBITION OF NF-kB

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58963704P 2004-07-20 2004-07-20
US60/589,637 2004-07-20

Publications (2)

Publication Number Publication Date
WO2006012419A2 WO2006012419A2 (en) 2006-02-02
WO2006012419A3 true WO2006012419A3 (en) 2007-03-08

Family

ID=35786698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025884 Ceased WO2006012419A2 (en) 2004-07-20 2005-07-20 Inhibition of nf-kb

Country Status (4)

Country Link
EP (1) EP1771203A4 (en)
JP (3) JP2008507545A (en)
AU (1) AU2005267117C1 (en)
WO (1) WO2006012419A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090099191A1 (en) * 2006-02-02 2009-04-16 Gudkov Andrei V Inhibition of nf-kb
WO2009143290A2 (en) * 2008-05-20 2009-11-26 Cleveland Biolabs, Inc Inducing cell death by inhibiting adaptive heat shock response
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
GR1006794B (en) 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης The new sigma(σ)-receptor ligands with anti-apoptotic and/or pro-apoptotic properties over cellular biochemical mechanisms, with neuroprotective, anti-cancer, anti-metastatic and anti-(chronic) inflammatory action.
US20110060000A1 (en) * 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
KR101812952B1 (en) * 2016-09-07 2017-12-28 부산대학교 산학협력단 Composition for preventing or treating refractory cancer comprising Quinacrine
CN115212209B (en) * 2021-04-19 2023-11-28 中国科学院分子细胞科学卓越创新中心 An anti-tumor drug with immune adjuvant activity and promotion of immunotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001131066A (en) 1999-08-25 2001-05-15 Nippon Kayaku Co Ltd Apoptosis enhancer
WO2003074490A1 (en) * 2002-03-07 2003-09-12 Samjin Pharmaceutical Co., Ltd. 9-aminoacridine derivatives and process for the preparation thereof
WO2007059482A2 (en) * 2005-11-14 2007-05-24 Cleveland Clinic Foundation Modulation of immune responses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DEMEUNYNCK ET AL.: "Interest of Acridine Derivatives in the Anticancer Chemotherapy", CURRENT PHARMACEUTICAL DESIGN, vol. 7, 2001, pages 1703 - 1724, XP003008809 *
DENNY W.A.: "Acridine derivatives as chemotherapeutic agents", CURRENT MEDICINAL CHEMISTRY, vol. 9, 2002, pages 1655 - 1665, XP009073854 *
LEJEUNE ET AL.: "Clinical applications of TNF-a in cancer", CURRENT OPINION IN IMMUNOLOGY, vol. 10, 1999, pages 573 - 580, XP004327283 *
MCCORMICK D.L.: "Anticarcinogenic activity of quinacrine in the rat mammary gland", CARCINOGENESIS, vol. 9, 1988, pages 175 - 178, XP008117611 *
SOHN ET AL.: "High-throuhgput measurement of the Tp53 response to anticancer drugs and random compounds using a stable integrate", CARCINOGENESIS, vol. 23, 2002, pages 949 - 957, XP002366983 *

Also Published As

Publication number Publication date
JP2008507545A (en) 2008-03-13
AU2005267117B2 (en) 2012-06-21
AU2005267117A1 (en) 2006-02-02
JP2011219499A (en) 2011-11-04
WO2006012419A2 (en) 2006-02-02
EP1771203A4 (en) 2010-06-02
EP1771203A2 (en) 2007-04-11
JP2014074056A (en) 2014-04-24
AU2005267117C1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
AU2003243373A1 (en) Cell migration inhibiting compositions and methods and compositions for treating cancer
GB2442373B (en) Sequence -specific inhibition of small rna function
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
WO2008115262A3 (en) Hsp90 inhibitors containing a zinc binding moiety
IL180410A0 (en) Phthalazine derivatives as parp inhibitors
WO2006113470A3 (en) Cancer treatment by combined inhibition of proteasome and telomerase activities
ZA200705113B (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
EP1755574A4 (en) Pten inhibitors
EP1729761A4 (en) Cadasil treatment with cholinesterase inhibitors
WO2008054711A3 (en) Combined telomerase inhibitor and gemcitabine for the treatment of cancer
WO2005072713A3 (en) Cholinesterase inhibitors for treating inflammation
WO2009105217A3 (en) Complement inhibitors as therapeutic agents for treatment of cancer
WO2003039545A3 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
WO2006012419A3 (en) Inhibition of nf-kb
WO2005086971A3 (en) Anti-metastatic ability of mibefradil and gadolinium
EP1713474A4 (en) Indirubin derivatives having anticancer property against human cancer cell me
IL176772A0 (en) Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
AU2003298810A1 (en) NF-kB INHIBITORS AND USES THEREOF
GB0428522D0 (en) Retrotransposon inhibition in therapy
WO2005032595A3 (en) Methods and compositions for the inhibition of stat5 in prostate cancer cells
WO2006124904A3 (en) Cancer treatment by combined inhibition of telomerase and hsp90 activities
IL177197A0 (en) Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
HK1098376A (en) Use of renin inhibitors in therapy
HK1106431A (en) Novel farnesyl protein transferase inhibitors and their use to treat cancer
HK1110303A (en) Methods and compositions for treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007522754

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005267117

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005791579

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005267117

Country of ref document: AU

Date of ref document: 20050720

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005267117

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005791579

Country of ref document: EP